Matija Snuderl, M.D.
Associate Professor
Director of Molecular Pathology and Diagnostics

First Molecular Test in US to Better Detect Brain Tumors Now Available to Patients

NYU Langone’s Department of Pathology collaborated with the German Cancer Research Center (DKFZ), Heidelberg, on the development of an epigenetic map of brain tumors reported in a scientific paper published in Nature in 2018.

“The study showed that 10 to 14 percent of brain tumors may be misdiagnosed using traditional diagnostics. We knew that DNA methylation can provide us with additional information not available by traditional techniques,” says Matija Snuderl, MD, Associate Professor in the Pathology Department, Director of Molecular Pathology and Diagnostics and a member of Perlmutter Cancer Center, who participated in the development of the methylation classifier and performed the clinical validation at NYU Langone.

In April 2019, NYU Langone Health became the first Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in the United States to receive state approval (New York State Department of Health) for whole genome DNA methylation for diagnosis and classification of brain tumors. More details: